Global Pain Management Market is Expected to Experience Immense Growth During 2020 – 2023

 Market Scenario

The global pain management market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the pain management market is expected to register a CAGR of 6.0% during the forecast period of 2018–2023.

Pain is considered as a clinical, social, and economic burden in communities around the world, as chronic pain is associated with various health conditions. The increasing prevalence of pain pushes the demand for better diagnosis and treatments.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5975

Notably, the market is expected to expand in the near future due to increasing technological advancements. The increasing occurrences of chronic pain conditions are continuously motivating marketers to come up with more technologically advanced products. For instance, a new noninvasive neuromodulation device, Stimpod NMS460 was introduced by the Xavant Technology to treat the chronic intractable pain. The device has received an FDA approval on August 01, 2017.

According to a study published in the Current Pain and Headache Reports Journal in 2016, it was found that Peripheral Nerve Stimulation (PNS) is a widely accepted treatment procedure for chronic pain. The StimRouter neuromodulation system by Bioness, Inc is a PNS technology-based device specifically designed to treat chronic pain. The device received the FDA approval in 2015.

Various other factors such as increasing geriatric population, improved reimbursement policies in developed countries, the increasing prevalence of cancer pain, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global pain management market.

Despite these drivers, there are some issues associated with the pain management market. The high cost associated with the technology, lack of skilled or trained physicians, and poor healthcare system in low and middle-income countries may hamper the growth of the market.

Key Players

Some of the key players in the global pain management market are Abbott Laboratories, Abbvie, Allergan, Astellas Pharma, AstraZeneca plc, Bayer AG, Codman And Shurtleff, Inc, DJO Global LLC, Eli Lilly & Company, Endo Health Solutions, F. Hoffmann-La Roche Ltd, Forest Laboratories, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Mallinckrodt plc, Medtronic PLC, ST. Jude Medical, Inc., Boston Scientific Corporation, Pfizer Inc., Halyard Health, Inc., Smiths Medical, B. Braun Melsungen AG, Neurotech Na, Inc., Becton, Dickinson and Company, Nevro Corp., Merck & Co. Inc., Novartis AG, Purdue Pharma LP, Sanofi, Stryker Corporation, Teva Pharmaceuticals, and others.

Intended Audience

• Pharmaceutical Companies
• Medical Devices Companies
• Research and Development (R&D) Companies
• Government Research Institutes
• Academic Institutes and Universities

Segmentation

The global pain management market is segmented on the basis of type of pain management devices, type of pain management drugs, indication, mode of purchase, and end-user.

On the basis of type of pain management devices, the market is classified as neurostimulation devices, analgesic infusion pumps, and ablation devices. The neurostimulation devices are further segmented into Transcutaneous Electrical Nerve Stimulation (TENS) devices and Spinal Cord Stimulation (SCS) devices. Ablation devices are further segmented into RF ablation devices and cryoablation devices.

On the basis of type of pain management drugs, the market is classified as Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), anticonvulsants, anesthetics, opioids, antimigraine agents, antidepressants, and others. The opioids segment is further classified as oxycodones, hydrocodone, tramadol, morphine, codeine, fentanyl, meperidine, methadone, and others.

On the basis of indication, the market is classified as neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, fibromyalgia, chronic back pain, arthritic pain, migraine, post-operative pain, and others.

On the basis of the mode of purchase, the market is classified as over the counter and prescription-based.

On the basis of end-user, the market is classified as hospitals and clinics, pharmaceutical companies, medical device companies, research and academic institutes, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pain-management-market-5975

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Future Growth of Neurocutaneous Disorder Market is Expected to Grow Healthy CAGR till 2023

 Market Scenario

The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord.

These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late. These syndromes cannot be cured, but various treatments can assist to manage the symptoms and any health concern. Lately, significant advances have been made by the use of DNA testing to confirm these syndromes in some people.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5937

The three most common types of neurocutaneous syndromes are Tuberous sclerosis (TS), Neurofibromatosis (NF): Type I, Type II, and schwannomatosis, and Sturge-Weber disease.

Tuberous sclerosis (TS) is a non-cancerous growth that occurs in organs such as brain, eyes, kidneys, heart, lungs, bones, and skin. There is a 50% chance of children to develop TS if the parent is affected by it. Moreover, the Sturge-Weber Syndrome (SWS) causes malformations relating to the face, eye, and brain. It is estimated that about 1 in 20,000 to 50,000 live births may be affected with the Sturge-Weber syndrome.

Increasing government initiatives for ensuring the early diagnosis is supposed to be a significant driver of the market. Moreover, many guidelines are issued by government organizations to promote awareness related to effective prevention measures, globally. All these factors are expected to contribute to the market growth throughout the forecast period. Moreover, concerns regarding the safety of reprocessed instruments and stringent regulations for sterilization equipment manufacturers and service providers are factors hampering the market growth.

Global market for neurocutaneous disorders is expected to have a CAGR of approximately 6.5% during 2017 to 2023.

Segmentation

The global neurocutaneous disorder market has been segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global neurocutaneous disorder market can be segmented into Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-weber syndrome, Ataxia-Telangiectasia (A-T), Von Hippel-Lindau disease (VHL), and others.

Neurofibromatosis (NF) is further divided into Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and schwannomatosis. The Sturge-weber syndrome is divided into type-1, type-2, and type-3.

On the basis of diagnosis, the global neurocutaneous disorder market can be segmented into skull radiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Electroencephalogram (EEG), genetic tests (blood testing), biopsy, and others

On the basis of treatment, the global neurocutaneous disorder market can be segmented into medication, laser therapy, surgical procedures, and others.

Medication is further divided into antiepileptic, beta-antagonist eye drops, carbonic anhydrase inhibitors, adrenergic eye drops, miotic eye drops, and others. Surgical procedures are further divided into focal cortical resection, hemispherectomy, corpus callosotomy, trabeculectomy, filtration surgery, cyclocryotherapy, Vagal Nerve Stimulation (VNS), and others.

On the basis of end-user, the global neurocutaneous disorder market is segmented into hospitals and clinics, diagnostic centers, and others.

Regional Analysis

The global neurocutaneous disorder market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region accounted for the largest market share of the global neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers. As per the National Institute of Neurological Disorders and Stroke (NINDS) in 2017, Neurofibromatosis Type 1 (NF1) occurs in about 1 in 3,000 to 4,000 births in the U.S. This condition is a chromosomal disorder which is inherited from a parent. Moreover, Neurofibromatosis Type 2 (NF2) occurs less frequently, affecting about 1 in 25,000 births in the U.S.

The European neurocutaneous disorder market is the second largest market followed by Asia Pacific. The Asia Pacific region is expected to exhibit the fastest growth throughout the forecast period owing to the exceptional healthcare standards and infrastructure, rising healthcare expenditure, and growing presence of outsourcing organizations across this region. Moreover, the presence of various government organizations dedicated to improving the standards for neurocutaneous disorders is among the significant factors contributing towards the growth of the Asia Pacific region.

The Middle Eastern region is expected to grow at a steady pace owing to factors such as the extensive development of the healthcare infrastructure and increasing R&D activities in the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/neurocutaneous-disorder-market-5937

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Paroxysmal Supraventricular Tachycardia Market – A market with high CAGR and return on investment by 2023

 Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.

The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5918

The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.

The global Paroxysmal Supraventricular Tachycardia (PSVT) market is expected to register a CAGR of approximately 6.50% during the forecast period, 2017–2023.

Segmentation

The global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).

On the basis of diagnosis, the Global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.

On the basis of treatment, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.

On the basis of end-user, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.

Regional Analysis

The global Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.

Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.

The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of this market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/paroxysmal-supraventricular-tachycardia-market-5918

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Obesity Treatment Market Research Report 2020 Analysis and Forecast to 2023

 Market Scenario

Obesity is a disorder characterized by an excessive amount of body fat. The medical condition not only generates cosmetic concerns but is also related to various diseases and health problems, including heart diseases, diabetes, and others. A variety of treatment options are available in the market for obesity treatment, which ranges from medications to surgeries. Growing obese population and increasing acceptance of bariatric surgeries are expected to be the major drivers for the market growth during the forecast period. The Monash University stated that Australia recorded a burgeoning number of bariatric surgeries in 2015, accounting for approximately 15,000 procedures within the region. Moreover, the increasing demand for minimally invasive surgeries, rising awareness, and favorable reimbursement policies are expected to boost the market growth during the forecast period. However, factors such as high cost of surgery followed by the risks of infection and anesthesia allergy and low healthcare expenditure in the middle and low-income countries are estimated to restrain the market growth during the forecast period. According to a study published in the Obesity Surgery Journal in 2017, the mean total cost for bariatric procedures such as gastric bypass or adjustable gastric banding was estimated to be around USD 14,389.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5872

The Global Obesity Treatment Market is expected to grow at an approximate CAGR of 16.7% during forecast period.

Segmentation

The global obesity treatment market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into inactivity obesity, food obesity, anxiety obesity, venous obesity, atherogenic obesity, and gluten obesity. On the basis of diagnosis, the market is categorized into blood tests, physical examination, and others. The blood tests segment is sub-segmented into cholesterol test, liver function test, thyroid test, and others. The physical examination segment is sub-segmented into heart rate measurement, blood pressure measurement, and others. On the basis of treatment, the market is segmented into medication, surgery, lifestyle changes, and others. The medication segment is sub-segmented into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment is sub-segmented into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others. On the basis of end-user, the market is segmented into hospitals, clinics, pharmacies, and others.

Key players

Some of the key players for the global obesity treatment market are VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.

Regional Analysis

The Americas dominates the global market for obesity treatment due to an increasing obese population and presence of a well-developed healthcare sector. Moreover, factors such as changing lifestyle, the presence of developed economies, and increasing healthcare expenditure boost the market within the Americas.

Europe follows the Americas and stands second in the global obesity treatment market. The availability of funds for research, growing obese population, and increasing adoption of bariatric surgeries within the region are estimated to drive the market within the region. As per the Eurostat in 2016, more than half of the adults, accounting for 51.6% of the total population living within the European Union were estimated to be overweight. On a regional basis, Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market in developed economies such as Italy, the U.K., France, and others.

Asia Pacific is estimated to be the fastest growing region and provides huge opportunities for the market growth. This can be attributed to the increasing obese population, continuously developing economies, and a growing healthcare sector within the region.  From 2014–2015, the Australian Institute of Health and Welfare stated that approximately two-thirds, i.e., 63% of the Australian population, aged 18 or more, were estimated to be overweight or obese.

On the other hand, the Middle East and Africa holds the least share in the global obesity treatment market due to the presence of poor economies and stringent government policies, especially within the Africa region. A majority of the market of the Middle East and Africa is estimated to be held by the Middle East.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/obesity-treatment-market-5872

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Delirium Market: Information, Analytical Insights and growth of 2020 – 2023

 Market Scenario

Delirium is a neurological (nervous system) condition and a serious disturbance in mental abilities that causes mental confusion and emotional disruption. Delirium can be caused due to various factors such as older age, exposure to certain medications, alcohol abuse, surgery or other medical procedures, factors such as exposure to toxic or infectious agents, physical trauma, diet, and behavioral and occupational factors.

The global delirium market is majorly driven by the increasing prevalence of neurological disorders and increasing older population leading to rise in patient population. Additionally, increasing government initiatives, increasing programs to create awareness, and market players offering advanced products are likely to drive the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5850

According to the United Nations, in 2017 approximately over 962 million population was aged over 60 and above globally. United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. This rising aging population is likely to propel the growth of global delirium market. Lack of awareness regarding the treatment is likely to hamper the growth of the market.

The Global Delirium Market is expected to grow at a CAGR of 6% during the forecast period.

Segments  

The global delirium market is segmented on the basis of type, treatment, diagnosis, and end-user.

On the basis of type, the market is segmented into hyperactive, hypoactive, and mixed.

On the basis of diagnosis, the market is segmented into laboratory tests, imaging tests, and physical examination. On the basis of laboratory tests, it is further sub-segmented into blood tests and urine tests. On the basis of imaging tests, it is further sub-segmented into brain-imaging tests.

On the basis of treatment, the market is segmented into antipsychotics and supportive care. On the basis of treatment, antipsychotics is further sub-segmented into risperidone, olanzapine, and quetiapine.

On the basis of end-user, the market is segmented into specialty centers, hospitals, and research centers.

Regional Analysis

The North American delirium market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing prevalence of delirium affected the population, along with the increasing older population is likely to drive the market. Additionally, the growing healthcare infrastructure along with the increasing government support is likely to enhance the growth of delirium market in North America. For instance, according to the National Institute of Mental Health, in 2016, around 6.75 of adults in the U.S. were reported to have undergone depression.

Europe is the second largest market and holds a healthy share in the global delirium market. The European market is expected to grow at a strong growth rate during the forecast period owing to the accessibility of advanced treatment facilities and rising skilled medical professionals along with the growing need for better healthcare set-up. Furthermore, the increasing older population, along with growing inclination towards sedentary lifestyle are driving the growth of the delirium market.

Asia Pacific is expected to be the fastest growing market. The increasing prevalence of chronic diseases and infections is the major driver for the market growth. China is the fastest growing region owing to an increasingly older population and rising patient population. The increasing awareness regarding health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and rise in the standard of living are driving the growth of the delirium market in the Asia Pacific region.

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the rise in healthcare development and rising demand for availability of specialty care centers.

Key Players       

Some of the key players in the Delirium market are Dr. Franz Kohler Chemie GmbH, Fraser Health, Gaia BioPharma Ltd., Novartis AG, Pfizer, Inc., Regenstrief Institute, Inc., and Air Liquide Sante International, among others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/delirium-market-5850

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Cervical Cancer Treatment Market Projected to Witness Vigorous Expansion by 2023

 Market Synopsis

The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer develops in the cells of the cervix. Strains of Human Papillomavirus (HPV), a sexually transmitted infection, play a role in causing most of the cervical cancers. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. Squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas are three types of cervical cancers. Squamous cell carcinomas develop from cells in the exocervix while adenocarcinomas develop from gland cells. The cancer cells are said to have features of squamous cells under the microscope. Adenosquamous carcinomas feature both squamous cell carcinomas and adenocarcinomas. Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are various treatment options for cervical cancer. Cystoscopy, proctoscopy, examination under anesthesia, and imaging studies such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), intravenous urography, and Positron Emission Tomography (PET scan) are used of the diagnosis of cervical cancer.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5834

The cervical cancer treatment market is mainly driven by the increasing prevalence of cervical cancer and increasing awareness about cervical cancer among women. Furthermore, the increasing demand for early diagnosis and treatment of cervical cancer is also expected to fuel the growth of the market during the review period. However, the high cost of treatment also fuels the growth of the market. The World Health Organization (WHO) stated that cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths.

Global Cervical Cancer Treatment market is expected to grow at a CAGR of 6.5% during the forecast period.

Segments

The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user.

On the basis of type, the market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.

On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others.

Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others.

Radiation Therapy is further segmented into external beam radiation and brachytherapy

Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others.

Targeted therapy is further segmented into bevacizumab and pazopanib.

Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone.

On the basis of end-user, the market is segmented into cancer care centers, diagnostic centers, pharmacies, and others.

Regional Analysis of the Global Cervical Cancer Treatment Market                 

Globally, Americas is the largest market for cervical cancer treatment whose growth is attributed to technological advancements in the field of oncology, increasing prevalence of cervical cancer, and development of new imaging devices by key players in the market. In North America, the market is driven by the increasing awareness of causes and risk factors of cervical cancer and its treatment. In the U.S., the market is driven by the increasing importance of women healthcare and changing lifestyle of women. South America exhibits a steady growth in the cervical cancer treatment market.

In the European countries, the growth of the market is attributed to a number of healthcare institutions offering treatment of cancer and huge investments in research and development activities by the U.K. and Germany. In Germany, the market is mainly driven by an increase in the use of new technological devices for the diagnosis and treatment of cancer.

In Asia Pacific, the cervical cancer treatment market exhibits numerous growth opportunities due to rising awareness about cervical cancer and the increasing demand for cost-effective treatment solutions such as chemotherapy. Japan, China, and India are the largest contributors to the market growth where the market is driven by the increasing emphasis on cancer detection and treatment and the rising prevalence of cancer. Additionally, availability of skilled healthcare professionals in research also accelerates the growth of the market. The increasing government support of oncology research and women healthcare initiatives and the rapid growth of the healthcare imaging industry in India and China fuel the f=growth of the market in the regions.

In the Middle East, Saudi Arabia and the United Arab Emirates (U.A.E.) are the largest contributors to the market growth due to the focus on the development of new healthcare facilities catering to the needs of cancer patients and availability of technologically advanced diagnostic devices of management. In African countries, the increasing number of healthcare initiatives for women health and improvement in healthcare infrastructure are likely to boost the growth of the market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cervical-cancer-treatment-market-5834

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Bone Metastasis Market - Factors Driving Growth Post 2023

 Market Scenario

Bone metastasis is characterized by the spreading of cancerous cells from their original site to a bone. All types of cancer can show bone-metastasis. However, it is estimated that breast cancer and prostate cancer are commonly associated with the disease. The medical condition is frequent for spine, pelvis, and thighs. Urinary incontinence, bowel incontinence, and hypercalcemia are some of the common symptoms of the disease. The increasing prevalence of bone metastasis is expected to be a major driver for the market growth during the forecast period. According to a study published in the Oncology Reviews Journal in 2017, the relative occurrence of bone metastasis was estimated to be around 65 to 75% for both breast and prostate cancers suffering patients, respectively. Moreover, the growing geriatric population, increasing healthcare expenditures, and increasing R&D in the market are estimated to drive the market growth during the forecast period. According to the American Society of Clinical Oncology in 2016, approximately 60% of the total cancer patients aged 65 years or more. However, factors such as lack of healthcare services in low-income countries, the high cost of treatment, and related side effects are estimated to restrain the market growth during the forecast period. According to a study published in the Journal of Spine Surgery in 2017, the mean total cost of therapeutic modalities such as vertebroplasty was estimated to be about USD 14,114 in 2014.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5776

The global bone metastasis market is expected to grow at an approximate CAGR of 8.4% during the forecast period

Intended Audience

• Pharmaceutical Companies
• Biotechnological Institutes
• Government and Private Laboratories
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Market Research and Consulting Service Providers

Segmentation

The global bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.

On the basis of diagnosis, the market is categorized into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.

On the basis of the treatment, the market is segmented into medical therapies, surgery, medication, and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others. The ablation therapy segment is further segmented into radiofrequency ablation, cryoablation, and others. The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and others. The medication segment is sub-segmented into pain medications, bone building medications, and others. The pain medication segment is sub-segmented into ibuprofen, morphine, and others. The bone-building medications segment is sub-segmented into corticosteroids, bisphosphonates, and others. The bisphosphonates segment is further segmented into teriparatide, pamidronate, medronate, and others.

On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, pharmacies, and ambulatory surgical centers.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bone-metastasis-market-5776

 

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com